Empagliflozin prevents heart failure through inhibition of the NHE1-NO pathway, independent of SGLT2.
Chen S, Wang Q, Bakker D, Hu X, Zhang L, van der Made I, Tebbens AM, Kovácsházi C, Giricz Z, Brenner GB, Ferdinandy P, Schaart G, Gemmink A, Hesselink MKC, Rivaud MR, Pieper MP, Hollmann MW, Weber NC, Balligand JL, Creemers EE, Coronel R, Zuurbier CJ.
Chen S, et al. Among authors: schaart g.
Basic Res Cardiol. 2024 Oct;119(5):751-772. doi: 10.1007/s00395-024-01067-9. Epub 2024 Jul 24.
Basic Res Cardiol. 2024.
PMID: 39046464
Free PMC article.